TOP > 外国特許検索 > PEPTIDE HAVING ACCUMULATION SPECIFIC TO PANCREATIC CANCER, AND USE OF SAID PEPTIDE

PEPTIDE HAVING ACCUMULATION SPECIFIC TO PANCREATIC CANCER, AND USE OF SAID PEPTIDE

外国特許コード F170009109
整理番号 (S2016-0035-N0)
掲載日 2017年6月23日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP081287
国際公開番号 WO 2017086090
国際出願日 平成28年10月21日(2016.10.21)
国際公開日 平成29年5月26日(2017.5.26)
優先権データ
  • 特願2015-226228 (2015.11.19) JP
発明の名称 (英語) PEPTIDE HAVING ACCUMULATION SPECIFIC TO PANCREATIC CANCER, AND USE OF SAID PEPTIDE
発明の概要(英語) The present invention provides a novel peptide having specific accumulation that acts directly on pancreatic cancer cells and tissues. The present invention is a peptide of (a) or (b) below. (a) A peptide comprising an amino acid sequence that includes a sequence represented by any of SEQ ID NOS: 1, 2, 3, or 4. (b) A peptide having accumulation specific to pancreatic cancer, the peptide comprising an amino acid sequence that has 60% or greater identity with a sequence represented by any of SEQ ID NOS: 1, 2, 3, or 4.
従来技術、競合技術の概要(英語) BACKGROUND ART
Pancreatic cancer (particularly, invasive pancreatic duct cancer) is, the mean survival time after diagnosis and about 6 months before, among the malignant tumors are known to be refractory. According to the publication of the population demographics Welfare, deaths a year-tumor is increasing year after year, statistically (2009 year) Heisei 21st a person 26,791. In addition, death of all cancer deaths from pancreatic cancer accounts for 9%, lung cancer, gastric cancer, colon cancer, hepatic cancer then in the second position 5. (1999 Year) national pancreatic cancer according to registered Surveillance, pancreatic cancer cases can be cut, in 39% of all cases. Further, 5 - year survival rate is as low as 13%.
Reason difficult to treat pancreatic cancer, early in the state of the subjective symptom is small, and is extremely difficult to provide early detection. Cancer progressing, abdominal pain, weight loss, the appearance of symptoms such as jaundice, to be found in many cases, in the majority of cases, already at the time of discovery obvious symptom expression when there is no adaptive surgery, surgery or makeshift was restricted to the treatment of advanced cancer state. In addition, another reason for such, or metastatic pancreatic cancer that is infiltrated from an early stage and it has the property of being easily. As for other reasons, in radiosurgery, retroperitoneal pancreas is located on the back side of many for intraperitoneal organs, pancreas only the affected area is exposed to the radiation and it is difficult to point. Therefore, the radiation treatment may, cause serious side effects is likely to, be applied outside of the choice of therapy.
Current, pancreatic cancer as a test or diagnostic method, for example, blood biochemical tests, abdominal ultrasound examination, endoscopic retrograde biliary contrast (Endoscopic retrograde cholangiopancreatography: ERCP) pancreatic inspection, in combination with computed tomography contrast agent (Computed Tomography: CT), magnetic resonance imaging (Magnetic resonance imaging: MRI), positron emission tomography (Positron Emission Tomography: PET) method (particularly, fluorodeoxyglucose (fluorodeoxy glucose: FDG) - PET method) and the inspection method of the like.
However, the peptide is utilized as a biomaterial in the trend in the medical field, Tat, penetratin, polyarginine such as a cell-membrane permeable peptide (cell-absorbable) is drawing attention. However, these peptides, tumor cells or normal cells or normal tissue and tumor tissue as well as the diffuse and non-selectively absorbed, target selection drug requires the delivery of the treatment of malignant tumors (Drag Delivery System) to apply the tool DDS, cause serious side effects in that it is difficult to use. In particular, worldwide Tat on a general-purpose experimental system such as a cell-membrane permeable (a cell-absorbable) peptide, the nature that gives rise to the liver has been known (for example, see non-patent document 1). On the other hand, the cyclic RGD, has been the only peptide pharmaceutical. Is cyclic RGD, or an existing blood vessel constituting the angiogenic vascular endothelial cells (and in some tumor cells) is highly expressed in reported αv β3 which targets integrin, upregulation of vascular permeability due to its action point, without a simultaneous combination alone in the form of other pharmaceutical and imaging agents and have been applied as DDS (for example, see Patent Document 1.).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • 発明者(英語)
  • KONDO Eisaku
  • SAITO Ken
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close